EMA Authorised: Rapamune (sirolimus) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Rapamune (sirolimus) for preventing graft rejection in kidney transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Kidney Transplantation

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection;Kidney Transplantation. MAH: Pfizer Europe MA EEIG. Decision date: 11/09/2025